GLSI
Greenwich LifeSciences, Inc.
+2.01 (+12.83%)17.64USD90.2K成交股數259M市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-12下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 5 · 97K · 1 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 97K · 0.00 |
| 近 180 天 淨額 | 97K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | 07-30 | Patel Snehal | CEO and CFO | P 公開市場買進 | 700 | 13.10 | 9K | 5.6M | SEC |
| 2026-07-28 | 07-30 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.5K | 13.59 | 20K | 5.6M | SEC |
| 2026-07-27 | 07-29 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.5K | 13.62 | 20K | 5.6M | SEC |
| 2026-07-24 | 07-27 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.1K | 12.88 | 14K | 5.6M | SEC |
| 2026-07-23 | 07-27 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.5K | 13.14 | 33K | 5.6M | SEC |
| 2026-01-13 | 01-15 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.8K | 29.83 | 54K | 5.6M | SEC |
| 2026-01-12 | 01-14 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.9K | 27.54 | 80K | 5.6M | SEC |
| 2025-12-31 | 01-05 | Patel Snehal | CEO and CFO | P 公開市場買進 | 4.3K | 21.36 | 92K | 5.6M | SEC |
| 2025-12-30 | 01-02 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.9K | 21.73 | 63K | 5.6M | SEC |
| 2025-12-18 | 12-19 | Patel Snehal | CEO and CFO | P 公開市場買進 | 4.1K | 12.62 | 52K | 5.6M | SEC |
| 2025-11-25 | 11-28 | Patel Snehal | CEO and CFO | P 公開市場買進 | 4.6K | 8.37 | 39K | 5.6M | SEC |
| 2025-11-07 | 11-12 | Patel Snehal | CEO and CFO | P 公開市場買進 | 10.6K | 8.43 | 89K | 5.6M | SEC |
| 2025-10-31 | 11-04 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.3K | 9.26 | 21K | 5.6M | SEC |
| 2025-04-25 | 04-29 | Patel Snehal | CEO and CFO | P 公開市場買進 | 3.6K | 9.88 | 36K | 5.6M | SEC |
| 2025-04-17 | 04-22 | Patel Snehal | CEO and CFO | P 公開市場買進 | 5.4K | 8.98 | 48K | 5.6M | SEC |
| 2025-04-07 | 04-08 | Patel Snehal | CEO and CFO | P 公開市場買進 | 3.6K | 9.10 | 33K | 5.6M | SEC |
| 2025-04-04 | 04-07 | Patel Snehal | CEO and CFO | P 公開市場買進 | 5.5K | 8.73 | 48K | 5.6M | SEC |
| 2025-01-10 | 01-13 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.5K | 12.51 | 31K | 5.6M | SEC |
| 2025-01-07 | 01-08 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.8K | 13.75 | 25K | 5.6M | SEC |
| 2025-01-06 | 01-08 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.1K | 13.31 | 15K | 5.5M | SEC |
| 2025-01-03 | 01-07 | Patel Snehal | CEO and CFO | P 公開市場買進 | 3.4K | 12.95 | 44K | 5.5M | SEC |
| 2025-01-02 | 01-06 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.0K | 11.97 | 24K | 5.5M | SEC |
| 2024-12-31 | 01-03 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.4K | 11.36 | 27K | 5.5M | SEC |
| 2024-12-30 | 01-02 | Patel Snehal | CEO and CFO | P 公開市場買進 | 3.2K | 11.12 | 36K | 5.5M | SEC |
| 2024-11-21 | 11-25 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 1.0K | 12.91 | 13K | 264K | SEC |
| 2024-09-26 | 09-30 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.5K | 14.63 | 22K | 5.5M | SEC |
| 2024-08-12 | 09-16 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 800 | 13.85 | 11K | 263K | SEC |
| 2024-08-06 | 08-08 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.0K | 13.81 | 28K | 5.5M | SEC |
| 2024-08-05 | 08-07 | Patel Snehal | CEO and CFO | P 公開市場買進 | 5.5K | 13.18 | 72K | 5.5M | SEC |
| 2024-08-02 | 08-05 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 1.0K | 15.15 | 15K | 262K | SEC |
| 2024-07-23 | 07-24 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.5K | 15.89 | 24K | 5.5M | SEC |
| 2024-07-18 | 07-22 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 1.0K | 16.00 | 16K | 261K | SEC |
| 2024-06-13 | 06-17 | Patel Snehal | CEO and CFO | P 公開市場買進 | 175K | 14.30 | 2.5M | 5.5M | SEC |
| 2024-04-01 | 04-03 | Patel Snehal | CEO and CFO | P 公開市場買進 | 3.0K | 19.08 | 57K | 5.4M | SEC |
| 2024-03-22 | 03-26 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.5K | 19.98 | 50K | 5.3M | SEC |
| 2024-03-20 | 03-22 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.5K | 17.68 | 27K | 5.3M | SEC |
| 2024-03-05 | 03-07 | Patel Snehal | CEO and CFO | P 公開市場買進 | 30.5K | 12.49 | 381K | 5.3M | SEC |
| 2024-03-05 | 03-07 | Patel Snehal | CEO and CFO | P 公開市場買進 | 3.5K | 12.49 | 44K | 5.3M | SEC |
| 2024-03-04 | 03-06 | Patel Snehal | CEO and CFO | P 公開市場買進 | 4.1K | 13.03 | 53K | 5.3M | SEC |
| 2024-02-16 | 02-21 | Patel Snehal | CEO and CFO | P 公開市場買進 | 10.8K | 11.16 | 121K | 5.3M | SEC |
| 2024-02-15 | 02-20 | Patel Snehal | CEO and CFO | P 公開市場買進 | 12.7K | 11.07 | 141K | 5.3M | SEC |
| 2023-11-10 | 11-14 | Patel Snehal | CEO and CFO | P 公開市場買進 | 5.0K | 10.17 | 51K | 5.3M | SEC |
| 2023-11-03 | 11-07 | Patel Snehal | CEO and CFO | P 公開市場買進 | 3.5K | 9.11 | 32K | 5.3M | SEC |
| 2023-10-27 | 10-31 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 500 | 8.57 | 4K | 260K | SEC |
| 2023-10-26 | 10-30 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.5K | 7.97 | 20K | 5.3M | SEC |
| 2023-10-25 | 10-27 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.5K | 7.91 | 20K | 5.3M | SEC |
| 2023-10-10 | 10-12 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 9.07 | 9K | 5.3M | SEC |
| 2023-10-04 | 10-05 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.0K | 8.63 | 17K | 5.3M | SEC |
| 2023-09-26 | 09-28 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 600 | 8.71 | 5K | 260K | SEC |
| 2023-09-19 | 09-21 | Patel Snehal | CEO and CFO | P 公開市場買進 | 4.0K | 8.95 | 36K | 5.3M | SEC |
| 2023-09-11 | 09-13 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 9.48 | 9K | 5.3M | SEC |
| 2023-08-22 | 08-24 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 9.97 | 10K | 5.3M | SEC |
| 2023-08-04 | 08-08 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.0K | 10.55 | 21K | 5.3M | SEC |
| 2023-07-21 | 07-25 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 9.20 | 9K | 5.3M | SEC |
| 2023-07-13 | 07-17 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 9.49 | 2K | 259K | SEC |
| 2023-05-17 | 05-18 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 11.69 | 12K | 5.3M | SEC |
| 2023-04-28 | 05-02 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 11.22 | 3K | 259K | SEC |
| 2023-04-19 | 04-21 | Patel Snehal | CEO and CFO | P 公開市場買進 | 7.0K | 11.10 | 78K | 5.3M | SEC |
| 2023-04-18 | 04-20 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.0K | 11.12 | 22K | 5.3M | SEC |
| 2023-04-11 | 04-12 | Patel Snehal | CEO and CFO | P 公開市場買進 | 5.0K | 12.42 | 62K | 5.3M | SEC |
| 2023-04-11 | 04-12 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 1.0K | 11.87 | 12K | 259K | SEC |
| 2023-03-15 | 03-16 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 12.71 | 3K | 258K | SEC |
| 2023-03-10 | 03-13 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 12.12 | 12K | 2.7M | SEC |
| 2023-02-24 | 02-28 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 15.40 | 4K | 257K | SEC |
| 2023-02-17 | 02-22 | Patel Snehal | CEO and CFO | P 公開市場買進 | 600 | 16.53 | 10K | 2.7M | SEC |
| 2023-02-10 | 02-14 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 18.68 | 19K | 2.7M | SEC |
| 2023-02-03 | 02-07 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 20.84 | 5K | 257K | SEC |
| 2023-01-27 | 01-31 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.0K | 19.35 | 39K | 2.7M | SEC |
| 2023-01-27 | 01-30 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 19.20 | 5K | 257K | SEC |
| 2023-01-20 | 01-24 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.5K | 17.37 | 26K | 2.7M | SEC |
| 2023-01-13 | 01-17 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 16.50 | 4K | 257K | SEC |
| 2023-01-06 | 01-10 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.5K | 15.18 | 23K | 2.7M | SEC |
| 2022-12-29 | 01-03 | Patel Snehal | CEO and CFO | P 公開市場買進 | 4.0K | 15.19 | 61K | 2.7M | SEC |
| 2022-12-16 | 12-20 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 13.01 | 13K | 2.7M | SEC |
| 2022-12-16 | 12-20 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 12.94 | 3K | 256K | SEC |
| 2022-12-09 | 12-13 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.0K | 13.11 | 26K | 2.7M | SEC |
| 2022-12-02 | 12-06 | Patel Snehal | CEO and CFO | P 公開市場買進 | 1.0K | 13.84 | 14K | 2.7M | SEC |
| 2022-12-02 | 12-06 | Thompson Jaye | VP Clinical Reg Affairs | P 公開市場買進 | 250 | 13.98 | 3K | 256K | SEC |
| 2022-11-02 | 11-04 | Patel Snehal | CEO and CFO | P 公開市場買進 | 2.0K | 8.79 | 18K | 2.7M | SEC |
| 2022-10-14 | 10-17 | Patel Snehal | CEO and CFO | P 公開市場買進 | 3.0K | 9.75 | 29K | 2.7M | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| BlackRock, Inc. | 486K | 11.4M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 278K | 6.5M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 168K | 3.9M | 新進 | 新進 |
| STATE STREET CORP | 143K | 3.4M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 80.9K | 1.9M | 新進 | 新進 |
| NORTHERN TRUST CORP | 80.2K | 1.9M | 新進 | 新進 |
| Bank of New York Mellon Corp | 47.9K | 1.1M | 新進 | 新進 |
| VANGUARD FIDUCIARY TRUST CO | 46.0K | 1.1M | 新進 | 新進 |
| MORGAN STANLEY | 43.4K | 1.0M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 39.3K | 923K | 新進 | 新進 |
| Russell Investments Group, Ltd. | 34.4K | 806K | 新進 | 新進 |
| JANE STREET GROUP, LLC | 27.7K | 650K | 新進 | 新進 |
| UBS Group AG | 23.4K | 549K | 新進 | 新進 |
| STATE OF WISCONSIN INVESTMENT BOARD | 22.6K | 531K | 新進 | 新進 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 17.9K | 420K | 新進 | 新進 |
| STRS OHIO | 17.8K | 418K | 新進 | 新進 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 17.1K | 401K | 新進 | 新進 |
| Vanguard Global Advisers, LLC | 11.9K | 278K | 新進 | 新進 |
| Ancora Advisors LLC | 10.7K | 252K | 新進 | 新進 |
| STIFEL FINANCIAL CORP | 10.0K | 235K | 新進 | 新進 |
| RAYMOND JAMES FINANCIAL INC | 9.1K | 214K | 新進 | 新進 |
| RHUMBLINE ADVISERS | 8.4K | 197K | 新進 | 新進 |
| WELLS FARGO & COMPANY/MN | 6.1K | 144K | 新進 | 新進 |
| DEUTSCHE BANK AG\ | 5.4K | 126K | 新進 | 新進 |
| FMR LLC | 4.0K | 94K | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 58 -6 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 58 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 1.7M · 11.5% |
| 合計季末市值 | 39.1M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 1.7M |
|---|---|
| 與上期比 | +4.2% |
| 佔流通股數 | 11.32% |
| 日均成交量 | 146K |
| 回補天數 | 11.4 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 1.7M | +4.2% | 11.32% | 146K | 11.4 |
| 2026-08-14 | 1.6M | +3.4% | 10.86% | 120K | 13.3 |
| 2026-07-31 | 1.5M | +5.0% | 10.50% | 215K | 7.2 |
| 2026-07-15 | 1.5M | +0.7% | 10.00% | 121K | 12.1 |
| 2026-06-30 | 1.5M | -0.2% | 9.93% | 169K | 8.6 |
| 2026-06-15 | 1.5M | -3.7% | 9.96% | 162K | 9.0 |
| 2026-05-29 | 1.5M | -1.5% | 10.34% | 114K | 13.4 |
| 2026-05-15 | 1.5M | -0.2% | 10.50% | 140K | 11.0 |
| 2026-04-30 | 1.5M | +1.4% | 10.52% | 141K | 11.0 |
| 2026-04-15 | 1.5M | +1.3% | 10.37% | 117K | 13.1 |
| 2026-03-31 | 1.5M | +5.9% | 10.24% | 201K | 7.5 |
| 2026-03-13 | 1.4M | +6.1% | 9.67% | 157K | 9.0 |
| 2026-02-27 | 1.3M | +4.5% | 9.11% | 132K | 10.1 |
| 2026-02-13 | 1.3M | -2.9% | 8.72% | 220K | 5.8 |
| 2026-01-30 | 1.3M | -14.7% | 8.98% | 999K | 1.3 |
| 2026-01-15 | 1.5M | -7.4% | 10.54% | 454K | 3.4 |
| 2025-12-31 | 1.7M | +3.1% | 11.37% | 912K | 1.8 |
| 2025-12-15 | 1.6M | +0.6% | 11.03% | 440K | 3.7 |
| 2025-11-28 | 1.6M | +1.7% | 10.97% | 58.9K | 27.3 |
| 2025-11-14 | 1.6M | +17.6% | 10.78% | 113K | 14.0 |
| 2025-10-31 | 1.3M | +0.3% | 9.17% | 67.7K | 19.9 |
| 2025-10-15 | 1.3M | -2.1% | 9.15% | 59.2K | 22.7 |
| 2025-09-30 | 1.4M | +11.1% | 9.34% | 84.4K | 16.3 |
| 2025-09-15 | 1.2M | +15.1% | 8.41% | 88.5K | 13.9 |
| 2025-08-29 | 1.1M | +1.0% | 7.31% | 33.8K | 31.7 |
| 2025-08-15 | 1.1M | +2.0% | 7.23% | 52.4K | 20.3 |